NCT07121829 2025-08-14Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsDay One Biopharmaceuticals, Inc.Phase 1 Terminated44 enrolled
NCT02723006 2024-03-05Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTakedaPhase 1 Terminated22 enrolled 14 charts